Literature DB >> 7332789

[Contribution of drill-biopsies to pre-treatment investigation of breast adenocarcinomas (author's transl)].

L Mauriac, J Wafflart, M Durand, B Parsi, I de Mascarel, M Trojani, C Meugé-Moraw.   

Abstract

The sensitivity of drill-biopsies (Rousseau's technique) was studied before using them routinely in pre-treatment investigation of breast adenocarcinomas. Results of histological examination, and estrogen (ER) and progesterone (PR) receptors levels obtained preoperatively by this technique, were compared with those from the corresponding mastectomy or tumourectomy specimens in 85 cases. Cytological examination of the various specimens, performed on prints, was used to compare their cellular density. Measurement of receptors included the determination of cytosolic and nuclear sites, and was performed by the single point dextran charcoal method. The limits of positivity established for ER and PR were 10 and 15 fM/mg protein respectively. The results showed sensitivity of 91.8 p. cent for pathology examinations; furthermore, the Scarff-Bloom-Richardson histoprognosis grading could be performed satisfactorily on drill-biopsy specimens. No significant difference was observed between the percentage of positivity for ER and PR from surgical and drill-biopsy specimens. Good correlation existed between values obtained from drill-biopsy and from surgery both for ER (r = 0.86, p less than 10(-5)) and PR (r = 0.86, p less than 10(-5)).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332789

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

1.  Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre.

Authors:  L Mauriac; M Durand; J Chauvergne; F Bonichon; A Avril; P Mage; M H Dilhuydy; A Le Treut; J Wafflart; D Marée
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

2.  Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.

Authors:  I Soubeyran; N Quénel; L Mauriac; M Durand; F Bonichon
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

3.  pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

Authors:  I Soubeyran; N Quénel; J M Coindre; F Bonichon; M Durand; J Wafflart; L Mauriac
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.